Background
Methods
Model
Parameters
Parameters | Value | Probability distribution |
---|---|---|
Baseline age | 40 | – |
Background mortality rate [30] | US life tables | – |
Monthly chance of death from hospitalization [31] | 0.0248 | Beta(1.099, 43.224) |
Standard therapy costs (per person week)a | ||
Controlled | $46 | – |
Partially controlled | $47 | – |
Uncontrolled | $53 | – |
Tiotropium | $13 | – |
Omalizumab | $437 | – |
Non-severe exacerbation | $130 | Gamma(100, 0.77) |
Severe exacerbation without hospitalization | $594 | Gamma(98.01, 0.17) |
Hospitalization | $9900 | Gamma(100.08, 0.01) |
Controlled | $165 | – |
Partially controlled | $185 | – |
Uncontrolled | $312 | – |
Exacerbation (Including not severe exacerbation, severe exacerbation and hospitalization) | $856 | – |
Controlled | 0.937 | Beta(982.3883, 66.0517) |
Partially controlled | 0.907 | Beta(378.5135, 38.8112) |
Uncontrolled | 0.728 | Beta(1212.6010, 453.0598) |
Non-severe exacerbation | 0.649 | Beta(1243.7040, 672.6349) |
Severe exacerbation without hospitalization | 0.570 | Beta(1175.3160, 886.6418) |
Hospitalization | 0.330 | Beta(613.7850, 1246.1690) |
Analysis
Sensitivity analysis
Results
Outcome | Standard therapy | Tiotropium | Omalizumab |
---|---|---|---|
Cost (95% CrI) | $38,432 ($32,075–$48,657) | $41,535 ($35,034–$54,699) | $217,847 ($214,477–$224,863) |
QALYs (95% CrI) | 6.79 (6.63–6.96) | 6.88 (6.69–7.07) | 7.17 (6.99–7.37) |
Number of weeks with non-severe exacerbations (95% CrI) | 20.04 (15.90–24.64) | 14.53 (11.07–18.87) | 9.92 (7.34–12.91) |
Number of weeks with severe exacerbations without hospitalization (95% CrI) | 11.39 (7.21–16.16) | 8.22 (5.03–11.97) | 7.15 (4.14–10.94) |
Number of hospitalizations (95% CrI) | 1.10 (0.45–2.19) | 1.05 (0.31–2.46) | 0.54 (0.14–1.48) |
ICER | |||
Tiotropium versus standard therapy | Reference | $34,478/QALY | – |
Omalizumab versus tiotropium | – | Reference | $593,643/QALY |
Omalizumab versus standard therapy | Reference | – | $463,605/QALY |